Telix Pharmaceuticals Limited (TLX)
Automate Your Wheel Strategy on TLX
With Tiblio's Option Bot, you can configure your own wheel strategy including TLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLX
- Rev/Share 3.5211
- Book/Share 1.2513
- PB 9.0061
- Debt/Equity 0.9913
- CurrentRatio 1.333
- ROIC 0.063
- MktCap 3814490022.748
- FreeCF/Share 0.0176
- PFCF 644.2883
- PE 109.333
- Debt/Assets 0.3515
- DivYield 0
- ROE 0.0702
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLX | Citigroup | -- | Buy | -- | $22 | Sept. 18, 2025 |
| Downgrade | TLX | JP Morgan | Overweight | Neutral | -- | -- | Aug. 28, 2025 |
| Initiation | TLX | H.C. Wainwright | -- | Buy | -- | $23 | July 3, 2025 |
| Initiation | TLX | Wedbush | -- | Outperform | -- | $22 | June 5, 2025 |
News
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.
Read More
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
Read More
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
Published: January 09, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
Read More
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Telix Pharmaceuticals Limited Investors to Act: Class Action Filed Alleging Investor Harm
Published: January 08, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Telix Pharmaceuticals Limited investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 1/5/2026
Read More
DEADLINE TOMORROW: Berger Montague Advises Telix Pharmaceuticals Ltd. (TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
Published: January 08, 2026 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: January 07, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 7, 2026 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU SUFFERED A LOSS ON YOUR TELIX INVESTMENTS, CLICK HERE BEFORE JANUARY 9, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: January 07, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
FRIDAY DEADLINE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
Published: January 07, 2026 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the “Class Period”).
Read More
TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
Portnoy Law Firm Announces Class Action on Behalf of Telix Pharmaceuticals Limited Investors
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Telix Pharmaceuticals Limited, (“Telix” or the "Company") (NASDAQ: TLX) investors of a class action on behalf of investors that bought securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2026 to file a lead plaintiff motion.
Read More
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
Read More
Telix (TLX) 4-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Published: January 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
Read More
TLX 7-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Published: January 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 02, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
Read More
ATTENTION TELIX PHARMACEUTICALS (TLX) SHAREHOLDERS: Securities Fraud Lawsuit Filed Against Telix Pharmaceuticals Ltd.
Published: January 02, 2026 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - January 2, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
TLX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
Published: January 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: January 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”).
Read More
UPCOMING DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
Published: January 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX
Published: January 02, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
Read More
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
Published: January 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Jan. 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 9, 2026.
Read More
21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
Published: January 01, 2026 by: PRNewsWire
Sentiment: Neutral
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: December 31, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa., Dec. 31, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
TLX CLASS ACTION DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
Published: December 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
Read More
TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
Published: December 31, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 31, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" or the "Company") …
Read More
Portnoy Law Firm Announces Class Action on Behalf of Telix Pharmaceuticals Limited Investors
Published: December 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Telix Pharmaceuticals Limited, (“Telix” or the "Company") (NASDAQ: TLX) investors of a class action on behalf of investors that bought securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). Telix investors have until January 9, 2026 to file a lead plaintiff motion.
Read More
TELIX PHARMACEUTICALS LTD. (TLX) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
Published: December 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - December 29, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: December 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 29, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Published: December 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: December 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
Read More
About Telix Pharmaceuticals Limited (TLX)
- IPO Date 2024-11-14
- Website https://telixpharma.com
- Industry Biotechnology
- CEO Christian Behrenbruch
- Employees None